Great Expectations in the Pipeline

P., Shankar
December 2007
njbiz;12/10/2007, Vol. 20 Issue 51, p1
The article focuses on upcoming drug products from NexMed, a pharmaceutical firm in East Windsor, New Jersey. The topically applied drug, known internally as NexMed's E.D. product, for erectile dysfunction, targets men who, for reasons that include side effects, cannot use any of the top three orally administered brands in the market for treating impotence. The other product bet for NexMed is an antifungal cream for nail infections, which is in Phase III trials, that it is developing in partnership with Novartis Pharmaceuticals.


Related Articles

  • FDA approves new quadrivalent meningococcal vaccine. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;4/1/2010, Vol. 67 Issue 7, p504 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) to the quadrivalent meningococcal vaccine Menveo of Novartis Pharmaceutical Corp. as announced by the company on February 22, 2010 which allows its marketing of the vaccine.

  • Afinitor Targets a Form Of Pancreatic Cancer.  // Chain Drug Review;6/6/2011, Vol. 33 Issue 10, p42 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) to Novartis Pharmaceuticals Corp.'s Afinitor drugs which can used for the treatment of progressive neuroendocrine tumors (NET) in East Hanover, New Jersey.

  • PRODUCT UPDATE. Mitchell, Sandra A. // Oncology Nursing Forum;Oct2001, Vol. 28 Issue 9, p1477 

    Presents news updates on various products related to the care of cancer patients in the U.S., as of October 2001. U.S. Food and Drug Administration drug approval for Zometa of Novartis Pharmaceuticals; Details of the drug Gleevec for the treatment of leukemia; Surface Safe from SuperGen for the...

  • FDA Expands Indication for Excelon Patch From Novartis.  // Chain Drug Review;8/5/2013, Vol. 35 Issue 12, p54 

    The article offers news briefs related to the health care industry including the U.S. Food and Drug Administration's (FDA) approval of a high-dose skin patch Exelon from Novartis Pharmaceuticals Corp., the availability of Qsymia capsules CIV and the approval of the Zubsolv tablets by the FDA.

  • OAB drug receives approvable letter.  // Urology Times;Nov2003, Vol. 31 Issue 11, p39 

    Reports on the U.S. Food and Drug Administration's approval of the drug darifenacin hydrobromide developed by pharmaceuticals firm Novartis Pharmaceuticals Corp.

  • NexMed Completes Study on Topical Impotence Treatment.  // Worldwide Biotech;Oct99, Vol. 11 Issue 10, p1 

    Reports on the announcement of NexMed Inc. on the evaluation of its proprietary alprostadil cream for treating male erectile dysfunction (MED) in a multiple-use clinical study in China that involved patients afflicted with MED. Results of the clinical study; Comments from Doctor Y. Joseph Mo,...

  • PHARMACY CORNER.  // Oncology Nursing Forum;May2007, Vol. 34 Issue 3, p737 

    The article offers news briefs on issues related to pharmaceuticals in the U.S. A Cancer and Leukemia Group B phase III clinical trial has found that arsenic trioxide may improve the condition of patients with acute promyelocytic leukemia (APL). Novartis Pharmaceuticals has unveiled the drug...

  • NEW FORMULATIONS.  // Drug Topics;6/5/2006, Vol. 150 Issue 11, p45 

    The article reports on the new higher-dose formulations approval of high blood pressure treatment drug, Diovan HCT from Novartis Pharmaceuticals Inc. by the U.S. Food and Drug Administration in 2006. The two new formulations for blood pressure medication are 320 over 12.5 milligram and 320 over...

  • EntreMed: testing Panzem potential in ovarian cancer.  // PharmaWatch: Monthly Review;Dec2006, Vol. 5 Issue 12, p7 

    The author reflects on the obstacles that Novartis Pharmaceuticals Corp.'s tumor and blood disorder drug Gleevec is facing in the U.S. According to the author, the drug is unlikely to have a significant achievement concerning its sales despite its approval by the Food and Drug Administration. He...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics